Last reviewed · How we verify
NCT06653361
Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy
NA trial testing Green laser in Proliferative Diabetic Retinopathy - High Risk in 120 participants. Completed in 28 February 2024.
28 February 2024
Quick facts
| Lead sponsor | Hayatabad Medical Complex |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 September 2022 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Green laser
Conditions studied
- Proliferative Diabetic Retinopathy - High Risk — all drugs for Proliferative Diabetic Retinopathy - High Risk →
Sponsor
Hayatabad Medical Complex — full company profile →
Who can join
Adults 18 to 80, any sex, with Proliferative Diabetic Retinopathy - High Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation. The study aims to compare ultra-widefield fluorescein angiography-based targeted retinal photocoagulation and panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation versus Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Controlled Trial.
Ahmad I, Mahsood YJ. · · 2025 · PMID 41244545 · DOI 10.12669/pjms.41.10.12535
Verify or expand the search:
- PubMed search for NCT06653361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Proliferative Diabetic Retinopathy - High Risk
Currently open trials in the same condition.
- NCT06899529 — Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy · NA · recruiting
Other Hayatabad Medical Complex trials
Trials by the same sponsor.
- NCT07522788 — Comparison Between Efficacy of Topical Tranexamic Acid Vs Topical Ethyl Ascorbic Acid In Treatment Of Melasma · Phase 4 · not yet recruiting
- NCT07422558 — Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain · NA · not yet recruiting
- NCT07460050 — Comparison of Two Sedative Agents in Terms of Controlled Hypotension · NA · not yet recruiting
- NCT07233382 — Assessing the Efficacy of Probiotics in Prevention of NEC in Preterm Babies · NA · not yet recruiting
- NCT07451990 — Comparison of Vicryl Versus Prolene for Midline Rectus Sheath Closure After Elective Laparotomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06653361 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hayatabad Medical Complex
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06653361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing